The Latest on the Intracept Procedure
Relievant Medsystems Announces Positive Local Coverage Determination by Palmetto GBA for Basivertebral Nerve Ablation in Treating Chronic Vertebrogenic Low Back Pain
MINNEAPOLIS – March 6, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that Palmetto GBA has published a final Local Coverage Determination...
Relievant Medsystems Announces Formal Coverage Recommendation from NASS for Basivertebral Nerve Ablation as a Treatment for Chronic Vertebrogenic Low Back Pain
MINNEAPOLIS – February 22, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that the North American Spine Society (NASS) issued a formal coverage...
Relievant Medsystems Announces Highest Quality of Evidence Ranking for Basivertebral Nerve Ablation in ASPN Back Guideline for Interventional Low Back Pain Treatments
MINNEAPOLIS – January 5, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that basivertebral nerve (BVN) ablation received a Grade A Quality of...
Relievant Medsystems Announces Updated Policy Statement and Guideline for Basivertebral Nerve Ablation from the International Society for the Advancement of Spine Surgery
MINNEAPOLIS – November 8, 2022 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that the International Society for the Advancement of Spine Surgery...
Relievant Medsystems Receives Most Promising New Product Award for the Intracept Procedure at the 27th Annual Phoenix Conference
MINNEAPOLIS – October 26, 2022 – Relievant Medsystems, a company focused on transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that its Intracept® Procedure has received the Most Promising New...
Pain Medicine Publishes Supplement Dedicated to Vertebrogenic Pain and Basivertebral Nerve Ablation
The August issue of Pain Medicine includes several peer-reviewed articles focusing on vertebrogenic pain – defining patient, clinical, and imaging factors associated with basivertebral nerve (BVN) ablation treatment success following the Intracept Procedure; and a...
Relievant Medsystems Announces Publication of ASPN Guidelines on the Diagnosis and Treatment of Vertebrogenic Low Back Pain with Basivertebral Nerve Ablation
Published guidelines with highest evidence rating provide physicians confidence to adopt basivertebral nerve ablation as first-line treatment MINNEAPOLIS – September 20, 2022 – Relievant Medsystems, a company focused on transforming the diagnosis and treatment of...
NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic Vertebrogenic Low Back Pain
Relievant Medsystems shared today that the company’s breakthrough chronic low back pain treatment, the Intracept Procedure, was featured on NBC’s TODAY this morning.
Relievant Medsystems Announces New Category I CPT Codes for Intracept® Procedure
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today that new Category I Current Procedural Terminology (CPT) codes for the Intracept Procedure are in effect as of January 1, 2022.
Relievant Medsystems Announces Publication of New INTRACEPT Trial Data Demonstrating Long-Term Relief for Chronic Low Back Pain 24 Months Post-Procedure
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 24-month results from a Level 1, prospective, randomized, multi-center trial (INTRACEPT) that further validate the safety, effectiveness, and durability of the Intracept® Procedure for patients with vertebrogenic CLBP.